Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CKD-391 (Atorvastatin + Ezetimibe) in Primary Hypercholesterolemia
NCT05657574Phase 3Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atorvastatin, ezetimibe in hypercholesterolemia, sponsored by Chong Kun Dang Holdings. Status: unknown.
02
Drugs
atorvastatinezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05657574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05657574.